Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia

Ueno, T.; Zenitani, M.; Yamanaka, H.; Tanaka, N.; Uehara, S.; Tazuke, Y.; Bessho, K.; Okuyama, H.

doi:https://doi.org/10.1016/j.transproceed.2016.02.011

Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia

Ueno, T.; Zenitani, M.; Yamanaka, H. et al.

Transplantation Proceedings, 2016, 48(4), 1095-1099

アクセス数:1,055件（2025-07-26 12:27 集計）

固定URL: https://hdl.handle.net/11094/98564

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日
TransplantProc_48_4_1095_abstract	pdf	なし	68.1 KB	13	2024.12.06
TransplantProc_48_4_1095_manuscript	pdf	なし	318 KB	22	2024.12.06
TransplantProc_48_4_1095_figure	pdf	なし	654 KB	14	2024.12.06
TransplantProc_48_4_1095_table	pdf	なし	136 KB	13	2024.12.06

Creative Commons : 表示 - 非営利 - 改変禁止

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia
著者	NRID 1000010456957 1000010456957 ORCID 0000-0002-4639-8814 0000-0002-4639-8814 researchmap permalink ueno-pedsurg ueno-pedsurg Scopus Author ID 21743992300 21743992300 著者名 Ueno, T.
	NRID 1000040643531 1000040643531 著者名 Zenitani, M.
	NRID 1000070467570 1000070467570 著者名 Yamanaka, H.
	NRID 1000020456958 1000020456958 著者名 Tanaka, N.
	NRID 1000000448060 1000000448060 著者名 Uehara, S.
	NRID 1000010397698 1000010397698 researchmap permalink yukotazuke-osaka yukotazuke-osaka Scopus Author ID 7006109798 7006109798 ORCID 0000-0002-8335-0414 0000-0002-8335-0414 著者名 Tazuke, Y.
	NRID 1000080423169 1000080423169 researchmap permalink KazuBe KazuBe 著者名 Bessho, K.
	NRID 1000030252670 1000030252670 researchmap permalink okuyamahiroomi okuyamahiroomi Scopus Author ID 35496082300 35496082300 ORCID 0000-0002-1347-282X 0000-0002-1347-282X 著者名 Okuyama, H.
内容	Ueno T., Zenitani M., Yamanaka H., et al. Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia. Transplantation Proceedings 48, 1095 (2016); https://doi.org/10.1016/j.transproceed.2016.02.011.
抄録	Background: Pediatric living donor liver transplant (LDLT) patients sometimes develop graft fibrosis after non-recurrent diseases such as biliary atresia (BA). Donor-specific antibodies (DSA) have recently been shown to play a possible role in graft damage after liver transplantation. We report the impact of DSA on pediatric LDLT for BA patients. Methods: Patients under age 18 years who received LDLT for BA at our institution and who had at least 5 years' follow-up were identified, and 23 were eventually enrolled in this study. Pathological findings were assessed with the use of the last available biopsy. Patients were divided into 2 groups, DSA-positive and DSA-negative. Graft fibrosis after LDLT was assessed according to DSA groups. Results: The mean patient age at transplant was 2.6 years. The mean time to the last available biopsy after LDLT was 8.2 years (4.8-15.6 years); 6 patients (26%) showed no fibrosis, whereas fibrosis was graded as F1, F2, or F3 in 8 patients (35%), 8 patients (35%), and 1 patient, respectively. DSA were observed in 12 patients (52%). Moderate graft fibrosis (F2 and F3) was found in 7 (58%) of the DSA-positive group, but only 2 (18%) of the DSA-negative group, showing a statistically significant difference (P <.05). Pre-transplant cross-matching was performed in 17 patients. The 2 patients with a positive cross-match were DSA-positive. Six cross-match-negative patients developed de novo DSA after LDLT. Conclusions: Graft fibrosis was observed after LDLT for BA during long-term follow-up, more commonly in DSA-positive patients. DSA may play a role in fibrosis formation.
会議情報	会議名 Congress of the Asian Society of Transplantation 回次 14 開催期間 August 23rd to August 25th, 2015 開催会場 Suntec Singapore Convention and Exhibition Centre 開催地 Singapore 開催国シンガポール
出版者	Elsevier USA
収録物名	Transplantation Proceedings
巻(号)	48(4)
ページ	1095-1099
刊行年月	2016-05-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/98564
PISSN	00411345
eISSN	18732623
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1016/j.transproceed.2016.02.011
アクセス権	open access
権利情報	©2024. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
出版タイプ	Accepted Manuscript
カテゴリ	会議発表論文 Conference Paper

資源タイプ	会議発表論文
ローカル資源タイプ	会議発表論文
DCTERMS.bibliographicCitation	Transplantation Proceedings. 2016, 48(4), p. 1095-1099
DC.title	Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia
DC.creator	Ueno, T.
	Zenitani, M.
	Yamanaka, H.
	Tanaka, N.
	Uehara, S.
	Tazuke, Y.
	Bessho, K.
	Okuyama, H.
DC.publisher	Elsevier USA
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2016-05-01
DC.identifier	https://doi.org/10.1016/j.transproceed.2016.02.011
DC.description	Ueno T., Zenitani M., Yamanaka H., et al. Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia. Transplantation Proceedings 48, 1095 (2016); https://doi.org/10.1016/j.transproceed.2016.02.011.
DCTERMS.abstract	Background: Pediatric living donor liver transplant (LDLT) patients sometimes develop graft fibrosis after non-recurrent diseases such as biliary atresia (BA). Donor-specific antibodies (DSA) have recently been shown to play a possible role in graft damage after liver transplantation. We report the impact of DSA on pediatric LDLT for BA patients. Methods: Patients under age 18 years who received LDLT for BA at our institution and who had at least 5 years' follow-up were identified, and 23 were eventually enrolled in this study. Pathological findings were assessed with the use of the last available biopsy. Patients were divided into 2 groups, DSA-positive and DSA-negative. Graft fibrosis after LDLT was assessed according to DSA groups. Results: The mean patient age at transplant was 2.6 years. The mean time to the last available biopsy after LDLT was 8.2 years (4.8-15.6 years); 6 patients (26%) showed no fibrosis, whereas fibrosis was graded as F1, F2, or F3 in 8 patients (35%), 8 patients (35%), and 1 patient, respectively. DSA were observed in 12 patients (52%). Moderate graft fibrosis (F2 and F3) was found in 7 (58%) of the DSA-positive group, but only 2 (18%) of the DSA-negative group, showing a statistically significant difference (P <.05). Pre-transplant cross-matching was performed in 17 patients. The 2 patients with a positive cross-match were DSA-positive. Six cross-match-negative patients developed de novo DSA after LDLT. Conclusions: Graft fibrosis was observed after LDLT for BA during long-term follow-up, more commonly in DSA-positive patients. DSA may play a role in fibrosis formation.
DC.rights	©2024. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
DC.format	98564
citation_title	Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia
citation_author	Ueno, T.
	Zenitani, M.
	Yamanaka, H.
	Tanaka, N.
	Uehara, S.
	Tazuke, Y.
	Bessho, K.
	Okuyama, H.
citation_publisher	Elsevier USA
citation_language	英語
citation_date	2016-05-01
citation_journal_title	Transplantation Proceedings
citation_volume	48
citation_issue	4
citation_firstpage	1095
citation_lastpage	1099
citation_doi	https://doi.org/10.1016/j.transproceed.2016.02.011
citation_public_url	https://hdl.handle.net/11094/98564

Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia

閲覧可能ファイル

論文情報

論文詳細を表示